Management of obesity in an individual with ROHHAD syndrome with semaglutide 2.4 mg/week: a case report
- PMID: 39340692
- DOI: 10.1007/s10286-024-01072-x
Management of obesity in an individual with ROHHAD syndrome with semaglutide 2.4 mg/week: a case report
Keywords: GLP-1; Obesity; ROHHAD.
Conflict of interest statement
Declarations. Conflict of interest: The authors did not receive support from any organization for the submitted work. JBB, ST, AS and AA received speaker honorarium or conference invitations from Novo Nordisk and Eli Lilly. Ethical approval: The patient provided informed consent for the publication of this case report. According to French regulations, ethical approval from an institutional review board is not required for case reports that describe standard care without experimental treatments. This study complies with local regulations, and the patient’s consent for the use of her medical data has been obtained and documented.
References
-
- Khaytin I, Victor AK, Barclay SF, Benson LA et al (2023) Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD): a collaborative review of the current understanding. Clin Auton Res 33(3):251–268 - PubMed
-
- Barclay SF, Rand CM, Gray PA, Gibson WT et al (2016) Absence of mutations in HCRT, HCRTR1 and HCRTR2 in patients with ROHHAD. Respir Physiol Neurobiol 221:59–63 - PubMed
-
- Patwari PP, Rand CM, Berry-Kravis EM, Ize-Ludlow D, Weese-Mayer DE (2011) Monozygotic twins discordant for ROHHAD phenotype. Pediatrics 128(3):e711–e715 - PubMed
-
- Chow C, Fortier MV, Das L, Menon AP et al (2015) Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD) syndrome may have a hypothalamus-periaqueductal gray localization. Pediatr Neurol 52(5):521–525 - PubMed
Publication types
LinkOut - more resources
Full Text Sources